1. Home
  2. CTNM vs CBFV Comparison

CTNM vs CBFV Comparison

Compare CTNM & CBFV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CTNM
  • CBFV
  • Stock Information
  • Founded
  • CTNM 2009
  • CBFV 1901
  • Country
  • CTNM United States
  • CBFV United States
  • Employees
  • CTNM N/A
  • CBFV N/A
  • Industry
  • CTNM
  • CBFV Major Banks
  • Sector
  • CTNM
  • CBFV Finance
  • Exchange
  • CTNM Nasdaq
  • CBFV Nasdaq
  • Market Cap
  • CTNM 174.6M
  • CBFV 153.2M
  • IPO Year
  • CTNM 2024
  • CBFV N/A
  • Fundamental
  • Price
  • CTNM $7.38
  • CBFV $31.63
  • Analyst Decision
  • CTNM Strong Buy
  • CBFV Buy
  • Analyst Count
  • CTNM 4
  • CBFV 2
  • Target Price
  • CTNM $22.50
  • CBFV $35.50
  • AVG Volume (30 Days)
  • CTNM 196.1K
  • CBFV 21.1K
  • Earning Date
  • CTNM 08-05-2025
  • CBFV 07-22-2025
  • Dividend Yield
  • CTNM N/A
  • CBFV 3.16%
  • EPS Growth
  • CTNM N/A
  • CBFV N/A
  • EPS
  • CTNM N/A
  • CBFV 2.15
  • Revenue
  • CTNM N/A
  • CBFV $50,822,000.00
  • Revenue This Year
  • CTNM N/A
  • CBFV $9.91
  • Revenue Next Year
  • CTNM N/A
  • CBFV $8.77
  • P/E Ratio
  • CTNM N/A
  • CBFV $14.73
  • Revenue Growth
  • CTNM N/A
  • CBFV N/A
  • 52 Week Low
  • CTNM $3.35
  • CBFV $24.49
  • 52 Week High
  • CTNM $20.55
  • CBFV $33.98
  • Technical
  • Relative Strength Index (RSI)
  • CTNM N/A
  • CBFV 55.59
  • Support Level
  • CTNM N/A
  • CBFV $30.00
  • Resistance Level
  • CTNM N/A
  • CBFV $32.91
  • Average True Range (ATR)
  • CTNM 0.00
  • CBFV 1.06
  • MACD
  • CTNM 0.00
  • CBFV -0.05
  • Stochastic Oscillator
  • CTNM 0.00
  • CBFV 41.27

About CTNM Contineum Therapeutics Inc. Class A Common Stock

Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

About CBFV CB Financial Services Inc.

CB Financial Services Inc operates as a bank holding company. The company conducts its operations through its wholly-owned subsidiary, Community Bank, a Pennsylvania-chartered commercial bank. The Bank offers products and services related to residential and commercial real estate loans, commercial and industrial loans, and consumer loans, as well as a range of deposit products for individuals and businesses in its market area. It operates in two operating units namely Community Banking and Insurance brokerage service segment. The bank generates its revenue in the form of interest.

Share on Social Networks: